CBER Director Peter Marks and former FDA Deputy Commissioner Janet Woodcock (Greg Nash/Pool via AP Images; Michael Brochstein/Sipa USA/Sipa via AP Images)
FDA's Marks, Woodcock talk regulatory flexibility for new rare disease drugs
The FDA’s top biologics chief and a former deputy commissioner on Tuesday discussed the need for regulatory flexibility for rare disease therapies and underscored the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
